Medigene AG Expands Patent Portfolio with European Patent Grant for its NY-ESO-1 – targeted T ...
Planegg/Martinsried, May 2, 2024. Medigene AG (Medigene or the “Company”, FSE: MDG1, Prime Standard), an immuno-oncology platform company focusing on the discovery and development of T cell immunotherapies for solid
Source: smdailyjournal.com